CLYM

NASDAQ 已收盘

Climb Bio

9.28 USD
▼-0.02-0.22%
盘后 10.80 0.00%
2026-11-19
市值
$539.80M
市盈率
—
EPS
-0.82
股息率
—
52 周区间
1.64 – 18.33
成交量
586.60K
Beta
-0.01
目标价
28.40
52W 低 1.6452W 高 18.33
价格走势

公司简介

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ...